How cost effective are subcutaneously anchored sutureless devices?

0

Every device must be efficient, safe and cost effective, but it is not enough to use it properly without considering the environment in which it will be employed. We applied this kind of analysis to subcutaneously anchored sutureless devices (SAS)” Zerla et al (2017).

Abstract:

Purpose: In recent years, a large variety of medical devices has become available. Every device must be efficient, safe and cost effective, but it is not enough to use it properly without considering the environment in which it will be employed. We applied this kind of analysis to subcutaneously anchored sutureless devices (SAS).

Methods: This is a one-center prospective observational study on safety, effectiveness and cost effectiveness of an SAS device (SecurAcath, Interrad) for securement of peripherally inserted central catheter (PICC) in 30 adult cancer patients with treatment expected to be >60 days.

Results: During 4963 catheter days and after 709 dressing changes (documented by 373 pictures), the use of SAS was associated with no episode of PICC dislodgement and a lower incidence of complications if compared to traditional securement devices. Insertion, management and removal of SAS were not associated with an increased pain perception by the patients. Cost effectiveness was particularly evident for long dwelling PICCs.

Conclusions: Our study suggests that SAS is a highly effective and cost-effective method for securement of medium- to long-term PICCs with expected duration longer than 30 days. The introduction of SAS had a positive impact on our healthcare organization.

Reference:

Zerla, P.A., Canelli, A., Cerne, L., Caravella, G., Gilardini, A., De Luca, G., Aricisteanu, A.M. and Venezia, R. (2017) Evaluating safety, efficacy, and cost-effectiveness of PICC securement by subcutaneously anchored stabilization device. The Journal of Vascular Access. February 15th. [Epub ahead of print].

doi: 10.5301/jva.5000655.

Thank you to our partners for supporting IVTEAM

Other stories

Loading…

Share.

Comments are closed.